Suven Life Sciences Ltd
NSE:SUVEN

Watchlist Manager
Suven Life Sciences Ltd Logo
Suven Life Sciences Ltd
NSE:SUVEN
Watchlist
Price: 131.06 INR -1.29% Market Closed
Market Cap: 28.6B INR
Have any thoughts about
Suven Life Sciences Ltd?
Write Note

Operating Margin
Suven Life Sciences Ltd

-1 964.1%
Current
-1 192%
Average
3.4%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 964.1%
=
Operating Profit
-1.7B
/
Revenue
84.1m

Operating Margin Across Competitors

Country IN
Market Cap 28.6B INR
Operating Margin
-1 964%
Country US
Market Cap 1.2T USD
Operating Margin
14%
Country US
Market Cap 200.7B USD
Operating Margin
17%
Country US
Market Cap 166.2B USD
Operating Margin
21%
Country KR
Market Cap 66.7T KRW
Operating Margin
31%
Country CH
Market Cap 38.4B CHF
Operating Margin
13%
Country US
Market Cap 38.6B USD
Operating Margin
24%
Country US
Market Cap 36.5B USD
Operating Margin
14%
Country US
Market Cap 27B USD
Operating Margin
28%
Country US
Market Cap 24.1B USD
Operating Margin
20%
Country CN
Market Cap 161.6B CNY
Operating Margin
27%
No Stocks Found

Suven Life Sciences Ltd
Glance View

Market Cap
28.6B INR
Industry
Life Sciences Tools & Services

Suven Life Sciences Ltd. engages on discovering, developing, and commercializing novel pharmaceutical products which are used in classic therapies. The company is headquartered in Hyderabad, Telangana and currently employs 117 full-time employees. The firm is focused on discovering and developing new chemical entities (NCEs), which are central nervous system therapies for the treatment of cognitive disorders, depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastrointestinal motility disorders. Its research targets include serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal and P2X purinoceptor 7 receptor. The company provides a range of Drug Discovery and Development Support Services (DDDSS). The firm offers research services specializing in synthetic, medicinal and analytical chemistry, in-vitro assay development and screening, drug metabolism and pharmacokinetics, toxicology and safety pharmacology, bioanalysis, and NCE formulations.

SUVEN Intrinsic Value
2.2 INR
Overvaluation 98%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 964.1%
=
Operating Profit
-1.7B
/
Revenue
84.1m
What is the Operating Margin of Suven Life Sciences Ltd?

Based on Suven Life Sciences Ltd's most recent financial statements, the company has Operating Margin of -1 964.1%.